# Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

> **NCT07133776** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Epstein-Barr Virus (EBV) Infection
- PD-1 Inhibitor
- Tenofovir
- Chidamide
- Lenalidomide

## Interventions

- **DRUG:** PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.

## Key facts

- **NCT ID:** NCT07133776
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07133776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07133776, "Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07133776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*